A daily dissolving route, considered clinically.
A clinician-selected compounded tirzepatide ODT with daily dissolving administration and route-specific prescribing.
Alternate dosage forms are compounded only where a licensed clinician documents a patient-specific clinical need that a commercially available product cannot meet. They are not interchangeable with, and are not substitutes for, FDA-approved products. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.
About 10 minutes. No charge unless your clinician approves.
One molecule, two incretin receptors, one delivery question.
Tirzepatide is a single peptide that binds and activates both the GIP receptor and the GLP-1 receptor, the targets of the two native incretin hormones. Most of this category acts on one of those pathways. Tirzepatide acts on both, and that is the reason a clinician reaches for this molecule rather than another.
What changes in this preparation is not the target. It is how the medication reaches you. This compounded tablet is designed to dissolve in the mouth rather than arrive by injection. That distinction can matter when injection intolerance, handling constraints, or a documented adherence problem makes the standard route a poor fit for a specific patient.
A daily dissolving route creates different questions from a weekly injection. The cadence and delivery differences can be explained without overclaiming absorption, while the clinical basis for compounding remains explicit.
Read the evidence →For when the molecule fits and the route does not.
The Injection-Intolerant
Needle phobia, injection-site reactions, or a physical limitation can make self-injection a real barrier rather than a preference. You want the route evaluated as part of the medical decision, not worked around.
The Handling-Constrained
Refrigeration, sharps disposal, shift work, or frequent travel can make an injectable plan hard to execute reliably. Your clinician weighs whether an alternate formulation makes the plan more followable.
The Documented Adherence Case
Your history carries more weight than a preference survey. If an injectable plan has already failed on execution rather than on response, that is material information for the prescribing conversation.
Compounded tirzepatide is not an FDA-approved drug product. This formulation is prescribed only where a provider determines the injectable route is unsuitable for you and documents that rationale. It is not selectable at checkout.
This might not be the right fit if:
- Personal or family history of medullary thyroid carcinoma or MEN 2
- History of pancreatitis
- Pregnancy, planned pregnancy, or breastfeeding
- Severe gastrointestinal disease, including gastroparesis
- Type 1 diabetes or insulin-dependent regimens without specialist oversight
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Tirzepatide ODT, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- Clinician review of whether an alternate route is documented as appropriate for you
- Compounded orally disintegrating tirzepatide prepared to the individual prescription
- Route-specific prescribing and adjustment rather than injection-dose substitution
- Follow-up tied to response, tolerability, and the wider metabolic plan
Alternate dosage forms are compounded only where a licensed clinician documents a patient-specific clinical need that a commercially available product cannot meet. They are not interchangeable with, and are not substitutes for, FDA-approved products. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Metabolic.
Semaglutide
A clinician on the other end of every dose.
Compounded semaglutide injection with clinician review, pharmacy fulfillment, shipping, and follow-up inside one care model. (Contains semaglutide.)
Tirzepatide
Two incretin pathways. One physician watching both.
Compounded tirzepatide injection built around dual GIP and GLP-1 receptor biology with clinician-directed dosing and follow-up. (Contains tirzepatide.)
Semaglutide + B12 Microdose
A lower-dose path with B12 built in.
A lower-dose compounded semaglutide and B12 prescription for clinician-guided metabolic care at a different starting scale. (Contains semaglutide and vitamin B12.)
What the research shows
Tirzepatide is one peptide that activates both the GIP and the GLP-1 receptor.
The detail
Tirzepatide is a single peptide that binds to and activates both the GIP receptor and the GLP-1 receptor, the targets of the two native incretin hormones.1
GIP and GLP-1 are gut peptides that produce the incretin effect after nutrient intake.
The detail
GIP and GLP-1 are gut peptides secreted after nutrient intake, GIP from K cells of the upper intestine and GLP-1 from L cells of the lower intestine, and together they produce the incretin effect, the larger insulin secretory response to oral than to intravenous glucose; GLP-1 is also glucagonostatic.2
Labeling says tirzepatide raises insulin, lowers glucagon and delays gastric emptying.
The detail
Approved tirzepatide labeling states that the molecule enhances first- and second-phase insulin secretion and reduces glucagon, both in a glucose-dependent manner, and that it delays gastric emptying, an effect largest after the first dose that diminishes over time.1
Labeling calls GLP-1 an appetite regulator; the GIP contribution rests on animal studies.
The detail
The same class of labeling describes GLP-1 as a physiological regulator of appetite and caloric intake, notes that GIP and GLP-1 receptors are found in areas of the brain involved in appetite regulation, and attributes the further contribution of GIP to food-intake regulation to nonclinical studies, with distribution to appetite-related brain regions shown in animal studies.3
What it does not show
None of the sources above evaluated a compounded preparation.
The detail
Approved-product labeling describes the pharmacokinetics and quality attributes of that finished product. It does not describe the exposure, potency or content of a preparation compounded to an individual prescription, and none of the sources above evaluated such a preparation.4
FDA does not verify the safety, effectiveness or quality of compounded drugs.
The detail
A compounded preparation is not an FDA-approved drug product, and FDA does not verify the safety, effectiveness or quality of a compounded drug before it is marketed.4
Everything above is mechanism from labeling, not trial results.
The detail
Every statement above is drawn from the clinical pharmacology section of approved labeling, a section separate from the clinical studies section of the same document. This block deliberately describes how the molecule works and does not report what any trial measured.1
Dual agonism is a statement about receptor binding, not about results.
The detail
Dual agonism means one molecule occupies two incretin receptors, a property characterized in vitro through receptor-occupancy analysis and cell signalling assays. It is a statement about receptor binding rather than a claim of results superior to agonism at the GLP-1 receptor alone.5
The central nervous system role of GIP in food intake was established in mice.
The detail
The central nervous system role of GIP receptor signalling in the control of food intake was established in mice, and rodent findings of that kind do not establish human outcomes.6
- FDA-approved tirzepatide injection prescribing information, sections…DailyMed
- Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018.
- FDA-approved tirzepatide injection prescribing information, section…DailyMed
- FDA, Compounding and the FDA: Questions and Answers.FDA
- Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor… JCI Insight. 2020. In vitro receptor pharmacology.
- Zhang Q, Delessa CT, Augustin R, et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body… Cell Metab. 2021.e5. Mouse study.
FDA-approved tirzepatide products carry a boxed warning about thyroid C-cell tumors observed in rats; whether tirzepatide causes these tumors in humans is unknown. That warning is why a personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication, and why pancreatitis history, pregnancy plans, significant gastrointestinal disease, and any glucose-lowering medication are reviewed before prescribing.
Do not use if you have
- A personal or family history of medullary thyroid carcinoma or MEN 2
Serious risks
- Pancreatitis
- Gallbladder disease
- Severe gastrointestinal reactions
- Kidney injury related to dehydration
- Hypoglycemia when tirzepatide is used with insulin or insulin secretagogues
Commonly reported
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
Because it is a compounded preparation
- This preparation is compounded rather than an FDA-approved finished drug product, so it has no safety database of its own
- Absorption through the oral route differs from subcutaneous injection, so exposure cannot be assumed to match an injectable product
The effects patients report most often are gastrointestinal, most often during titration. The important risks in tirzepatide labeling are listed here. Absorption through the oral route differs from subcutaneous injection, so exposure cannot be assumed to match an injectable product. The prescribing judgment stays with your clinician.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
Oral tirzepatide has not been studied in humans. Absorption through the oral route differs materially from subcutaneous injection, so this is not interchangeable with an injectable product and is not dosed like one. The randomized trials that support approved tirzepatide injections were run on those injections, and their results do not transfer to a compounded tablet. Your provider doses this for its own route and monitors your actual response.
Tirzepatide is an FDA-approved medicine. It is approved as a once-weekly injection, sold under two brand names, for type 2 diabetes and for chronic weight management. No orally disintegrating tirzepatide is FDA-approved, and this preparation is not the approved product. No compounded medication is FDA-approved, including this one. Compounded medicines are made to your individual prescription by a licensed pharmacy rather than manufactured and approved as a finished drug product.
They are different molecules. Semaglutide acts at the GLP-1 receptor. Tirzepatide activates both the GIP and the GLP-1 receptor in one peptide. Which one belongs in your plan is a clinical judgment that takes in your history, your tolerance, and what you have already tried, and it is your provider’s call rather than a menu choice.
Provider review, your prescription if approved, compounding and fulfillment by the pharmacy, shipping, check-ins, and messaging access to your care team. No separate visit fees. If your plan changes, your provider discusses it with you before your billing does.
The gastrointestinal effects typical of incretin therapy: nausea, diarrhea, constipation, and reflux, most noticeable while your dose is being adjusted. Some patients notice mild taste changes with an orally disintegrating tablet. Your provider manages side effects actively and can adjust dose, timing, or format.